Muutke küpsiste eelistusi

Primordial Prevention of Cardiovascular Disease [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 362 pages, kõrgus x laius: 235x155 mm, 20 Illustrations, color; 6 Illustrations, black and white
  • Sari: Contemporary Cardiology
  • Ilmumisaeg: 30-May-2026
  • Kirjastus: Humana
  • ISBN-10: 3032142555
  • ISBN-13: 9783032142559
Teised raamatud teemal:
  • Kõva köide
  • Hind: 187,84 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 220,99 €
  • Säästad 15%
  • See raamat ei ole veel ilmunud. Raamatu kohalejõudmiseks kulub orienteeruvalt 3-4 nädalat peale raamatu väljaandmist.
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 362 pages, kõrgus x laius: 235x155 mm, 20 Illustrations, color; 6 Illustrations, black and white
  • Sari: Contemporary Cardiology
  • Ilmumisaeg: 30-May-2026
  • Kirjastus: Humana
  • ISBN-10: 3032142555
  • ISBN-13: 9783032142559
Teised raamatud teemal:
This book is the first authoritative and comprehensive volume presenting basic, translational and clinical research demonstrating the importance of primordial, primary and secondary prevention starting in childhood for the reduction of adult cardiovascular diseases. Chapters will various childhood cardiovascular risk factors that predict adult cardiovascular and other health conditions. The book will also cover lessons learned from longitudinal cardiovascular cohorts such as the Bogalusa Heart Study, the Young Finns Study, and the Avon Longitudinal Study of Parents and Children. In addition, the book covers adolescent cohorts from low and middle-income countries. 



Primordial Prevention of Cardiovascular Disease will serve as the premier textbook for preventive cardiology across the lifespan and will serve as a valuable resource for physicians, residents, fellows and medical students in cardiology, primary care, and health promotion and disease prevention.



 
Section 1:  Evidence for the Importance of Primordial Prevention.-
Chapter
1. Pre-conception Health and Future CVD.
Chapter
2. Biological
Programming in the Perinatal Period:  animal studies.- 
Chapter
3. Biological
Programming in the Perinatal Period:  human studies.
Chapter
4.
Environmental Factors Increasing Risk for Cardiometabolic Disorders.
Chapter
5. Childhood Factors Predicting Adult Cardiometabolic Risk.
Chapter
6.
Childhood CV Risk Factors Predicting Adult Sub-clinical Target Organ Damage.-
Chapter
7. Childhood CV Risk Factors Predicting Adolescent and Young Adult
Target Organ Damage.
Chapter
8. Childhood CV Risk Factors Predicting Adult
CV Events.
Chapter
9. Primordial Prevention in the Young and reduction of CV
Risk Factors and Subclinical Disease in Adulthood.
Chapter
10. Lifestyle
Interventions to Reduce CV Risk in the Young.
Chapter
11. Pharmacologic
Therapy to Prevent CV Disease in High-Risk Youth.- Section 2: Lessons Learned
From Longitudinal CV Cohorts.
Chapter 12.  Bogalusa Heart Study.
Chapter
13. Young Finns Study.
Chapter
14. Cardiovascular Determinants of Adult
Risk.
Chapter
15. Muscatine Heart Study.
Chapter
16. Special Turku Risk
factor Intervention Project.
Chapter
17. Coronary Artery Risk Detection in
Appalachian Communities.
Chapter
18. National Longitudinal Study of
Adolescent to Adult Health.
Chapter
19. Avon Longitudinal Study of Parents
and Children.
Chapter
20. Atherosclerosis Risk in Young Adults.
Chapter
21.
Generation R.
Chapter
22. Kangwha Study.- 
Chapter
23. Adolescent Cohorts
from Low and Middle-income Countries.
Chapter
24. Synthetic Cohorts.
Elaine M Urbina, MD, MS, is the Professor Emeritus of Preventive Cardiology at the Cincinnati Children's Hospital Medical Center. Her clinical activities and industry sponsored grants focused on prevention (obesity, hypertension and dyslipidemias). Her research grants concentrated on new non-invasive methods of assessing atherosclerotic CV target organ damage in youth related to CV risk factors especially those that cluster with obesity. She has over 30 years of experience in non-invasive imaging of CV structure and function in large epidemiologic studies such as the Bogalusa Heart Study. She was the PI of a National Institutes of Health grant (NHLBI R01) following the cardiac and vascular effects of obesity and type 2 diabetes on adolescents and an American Heart Association grant evaluating the CV effects of hypertension in adolescents.  She is a member of the International Childhood CV Cohorts Consortium that will be following Bogalusa, Muscatine, Young Finns and other cohorts that collected CV risk factor data in children starting over 40 years ago with the participants now entering middle age.  



Sarah de Ferranti, MD, MPH, is an Associate Professor of Pediatrics at Harvard Medical School and Chief of the Ambulatory Cardiology Division at Boston Children's Hospital. She divides her time between clinical and implementation research, and caring for patients with preventive cardiology and congenital heart disease. Her research has included epidemiology, nutrition and pharmaceutical clinical trials, and more recently qualitative and modeling projects. Early on, she developed a definition of pediatric metabolic syndrome. Her first prospective research project, Inflammation in Children at High Risk for Atherosclerotic Disease, laid the ground work for a nutritional intervention in adolescents with metabolic syndrome supported by an Eleanor and Miles Shore Scholarship, and subsequently by NHLBI through the K23 mechanism, the first feeding study conducted at Boston Children's Hospital, and the first of its kind in overweight adolescents. She is currently MPI of the Boston Childrens Pediatric Heart Network center grant, and is Associate Director of the Departmental T32. Recent work has focused on Familial Hypercholesterolemia - screening, diagnosing and treating in childhood.